FCN-437c clinical trials
How each study uses FCN-437c is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the FCN-437c studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 6
Ahon Pharmaceutical Co., Ltd. (5) · Fochon Pharmaceuticals, Ltd. (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses FCN-437c is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast CancerRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07616427Written as FovinaciclibHow we know
- Clinical Trial of FCN-437c Capsule in Patients With Hepatic InsufficiencyCompletedPhase 1Ahon Pharmaceutical Co., Ltd.NCT06620731Written as FCN-437c capsuleHow we know
- This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.Status unknownPhase 3Ahon Pharmaceutical Co., Ltd.NCT05439499Written as FCN-437c, Letrozole or anastrozole, Goserelin acetateHow we know
- This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.Status unknownPhase 3Ahon Pharmaceutical Co., Ltd.NCT05438810Written as FCN-437c,Fulvestrant,Goserelin acetateHow we know
- Study of FCN-437c in Patients With Advanced Solid TumorsCompletedPhase 1Fochon Pharmaceuticals, Ltd.NCT03951116Written as FCN-437How we know
- Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+GoserelinStatus unknownPhase 2Ahon Pharmaceutical Co., Ltd.NCT05004142Written as FCN-437c+FulvestrantHow we know
- Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437cStatus unknownPhase 1/2Ahon Pharmaceutical Co., Ltd.NCT04488107Written as FCN-437cHow we know